Perspective Therapeutics, Inc. (CATX)
NYSEAMERICAN: CATX · Real-Time Price · USD
2.570
-0.130 (-4.81%)
May 30, 2025, 4:00 PM - Market closed
Perspective Therapeutics Revenue
Perspective Therapeutics had revenue of $342.00K in the quarter ending March 31, 2025, with 5.23% growth. This brings the company's revenue in the last twelve months to $1.47M, down -3.60% year-over-year. In the year 2024, Perspective Therapeutics had annual revenue of $1.45M with 1.39% growth.
Revenue (ttm)
$1.47M
Revenue Growth
-3.60%
P/S Ratio
122.54
Revenue / Employee
$10,507
Employees
140
Market Cap
190.31M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
CATX News
- 1 day ago - Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting - GlobeNewsWire
- 19 days ago - Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results - GlobeNewsWire
- 4 weeks ago - Perspective Therapeutics to Participate in Upcoming May Investor Conferences - GlobeNewsWire
- 5 weeks ago - Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting - GlobeNewsWire
- 6 weeks ago - Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results - GlobeNewsWire
- 7 weeks ago - Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma - GlobeNewsWire
- 2 months ago - Perspective Therapeutics to Participate in Upcoming April Investor Conferences - GlobeNewsWire
- 2 months ago - Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results - GlobeNewsWire